| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $352.5M | Series C | 8/9/2023 | $200M | $839.6M | $8.32 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | ||||
 | Encoded Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $945.89M | Series F | 9/9/2026 | $275M | $629.69M | $3.40 | GV, ARCH Venture Partners, Braidwell, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank, Venrock | ||||
 | Tessera Therapeutics | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $587.85M | Series D | 12/1/2025 | $200M | $668.33M | $5.18 | Bill & Melinda Gates Foundation, Regeneron | ||||
 | Precision Neuroscience | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $1.35M | -- | 3 | Not available | -- | -- | $182.65M | Series C | 12/16/2024 | $102M | $542.69M | $5.70 | General Equity Holdings, B Capital, Duquesne Family Office, Steadview Capital | ||||
 | Loyal | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $236.56M | Series C | 2/11/2026 | $95.46M | $614.38M | $12.26 | Age 1, Baillie Gifford | ||||
 | Neurona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $342.29M | Series F | 4/3/2025 | $101.71M | $578.63M | $2.06 | Fidelity, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, Spur Capital Partners | ||||
 | American Gene Technologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $72.88M | Series F-1 | 12/3/2021 | $18M | $712.6M | $12.00 | Ride Wave Ventures, Alumni Ventures | ||||
 | Nusano | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $474.68M | Series D-1 | 4/21/2026 | $180M | $655.01M | $1.25 | Undisclosed Investors | ||||
 | Cellanome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $307.18M | Series C | 12/22/2025 | $90.84M | $712.61M | $8.49 | Undisclosed Investors | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | Cellarity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $435.63M | Series D | 12/23/2024 | $196.06M | $517.83M | $3.60 | Undisclosed Investors | ||||
 | Latigo Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $287.9M | Series B | 3/17/2025 | $150M | $525.73M | $1.57 | Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments | ||||
 | Rakuten Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $874.92M | Series F-3 | 1/7/2026 | $3.6M | $636.9M | $1.03 | Taiwania Capital, Axil Capital Group, Daiwa Securities, Mitsui Sumitomo Insurance Company, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten, Mickey Mikitani | ||||
 | Cerapedics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series G | 6/5/2024 | $15.23M | $744.31M | $5.64 | Undisclosed Investors | ||||
 | Valo | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $406.25M | Series B | 3/9/2021 | $310M | $919.92M | $5.88 | PSP Investments, Flagship Pioneering, Invus Public Equities, HBM Healthcare Investments, Atinum Investment, Mirae Asset Capital, Koch Disruptive Technologies | ||||
 | Avenzo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $445.85M | Series B | 9/22/2025 | $60M | $616.96M | $2.22 | OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital, NEA, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital | ||||
 | Delfi Diagnostics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $326.47M | Series B | 7/18/2022 | $225M | $685.11M | $4.85 | DFJ Growth, Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, T. Rowe Price Associates, Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, Windham Venture Partners | ||||
 | Genesis Molecular AI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $340.28M | Series B-3 | 5/20/2026 | $40M | $806.79M | $9.33 | Incyte | ||||
 | Neurelis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.94M | Series D | 3/9/2021 | $114.76M | $544.18M | $3.15 | Cormorant Asset Management, Decheng Capital, LYZZ Capital, HBM Healthcare Investments, Philos & Partners SA | ||||
 | Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $413.6M | Series D | 9/10/2025 | $213.63M | $527.3M | $14.62 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | ||||
 | Bambusa Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $142.98M | Series A-2 | 11/17/2025 | $40M | $539.54M | $18.73 | Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners, Salvia, Janus Henderson Investors, Invus, ADAR1 Capital Management, Dawn Biopharma | ||||
 | Candid Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $370M | Series B | 9/9/2024 | $190.26M | $660.51M | $1.20 | Venrock, Fairmount Partners, TCG Crossover Management, venBio Partners, Foresite Capital, Third Rock Ventures, Fidelity, Samsara BioCapital, Qiming Venture Partners, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Partners, Soleus Capital | ||||
 | Embark | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $94.55M | Series B | 7/26/2021 | $75M | $759.47M | $16.96 | SoftBank, F-Prime Capital, SV Angel, Slow Ventures, Freestyle Capital, Third Kind Venture Capital | ||||
 | Rivus Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $224.04M | Series B-2 | 1/16/2025 | $122.98M | $506.82M | $4.76 | RA Capital Management, Bain Capital, BB Biotech AG, Longitutde Capital, Medicxi, RxCapital | ||||